Insurer Faces $25.5m Payout After Denial of Proton Therapy Insurer Faces $25.5m Payout After Denial of Proton Therapy
Health insurer Aetna denied proton therapy because it was'experimental.'This jury verdict raises the possibility that other denial-of-care suits will follow.Medscape Medical News
ConclusionsInstitution of a BP biologic dose constraint may reduce brachial plexopathy risk without compromising target coverage. MCBD plan evaluation provides valuable information to physicians that may assist in making clinical judgments regarding relative priority of target coverage versus normal tissue sparing.
Proton therapy developer Ion Beam Applications (IBA) and Azrieli Centre for...Read more on AuntMinnie.comRelated Reading: IBA takes next step in China deal IBA to install carbon therapy in France IBA posts revenue increase in 1st half of 2019 IBA inks deal to install cyclotron in South Korea IBA takes order from Kan.
Patient-specific collimators used in proton therapy are activated after use. The aim of this work is to assess the residual activity in brass collimators considering clinical beams, so far studied only for monoenergetic beams, and to develop a model to calculate the activity. Eight brass collimators irradiated with different clinical and monoenergetic beams were included in the study. The collimators were analyzed with gamma spectrometry in the framework of three independent studies carried out at the two French proton therapy sites. Using FLUKA (a fully integrated particle physics Monte Carlo simulation package), simulati...
Purpose of review Increased life expectancy in brain tumour patients had led to the need for strategies that preserve and improve cognitive functioning, as many patients suffer from cognitive deficits. The tumour itself, as well as antitumor treatment including surgery, radiotherapy and chemotherapy, supportive treatment and individual patient factors are associated with cognitive problems. Here, we review the recent literature on approaches that preserve and improve cognitive functioning, including pharmacological agents and rehabilitation programs. Recent findings Minimizing cognitive dysfunction and improving cogni...
In conclusion, this numerical study suggests that the ionoacoustic wave field may well be used to monitor the proton dose distribution during breast cancer treatment. PMID: 31600743 [PubMed - as supplied by publisher]
The U.S. Food and Drug Administration (FDA) has cleared proton therapy developer...Read more on AuntMinnie.comRelated Reading: ProTom files for bankruptcy protection ProTom begins installing synchrotron Proton therapy experts look back and to the future ProTom, MIT test accelerator
WAKEFIELD, Mass., Oct. 7, 2019 -- (Healthcare Sales &Marketing Network) -- ProTom International Holding Corporation ("ProTom"), a market-leading proton therapy technology manufacturer, announced that it has received 510(k) clearance from the U.... Devices, Oncology, FDA ProTom International, Radiance 330, proton therapy, radiotherapy
Publication date: Available online 2 October 2019Source: Practical Radiation OncologyAuthor(s): Bradford S. Hoppe, James E. Bates, Nancy P. Mendenhall, Christopher G. Morris, Debbie Louis, Meng Wei Ho, Richard Hoppe, Marwan Shaikh, Zuofeng L, Stella FlampouriAbstractBackground &PurposeMean heart dose (MHD) correlates with late cardiac toxicity among survivors of lymphoma receiving involved-field radiotherapy (IFRT). We investigated MHD and cardiac substructure dose across older and newer radiation fields and techniques to understand the value of evaluating MHD alone.Patients &MethodsFollowing IRB approval, we devel...
en BS PMID: 31578911 [PubMed - as supplied by publisher]
Publication date: Available online 1 October 2019Source: Hematology/Oncology Clinics of North AmericaAuthor(s): Michael J. LaRiviere, Patricia Mae G. Santos, Christine E. Hill-Kayser, James M. Metz